

Appointment of Independent, Deputy Chair

✓ Non-Executive Director, Sue MacLeman appointed to Independent, Deputy Chair.

Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to announce that Non-Executive Director, Ms Sue MacLeman has been elected to the new position of Independent Deputy Chair of the Board of the Company.

With Mr Otto Buttula, Executive Chair of the Company, having assumed additional executive duties within the Company since the end of April 2023, both the Executive and Board believe it is in the best interests of all stakeholders to elect an Independent, Deputy Chair.

Ms MacLeman was appointed a Non-Executive Director of the Company on 31 January 2023 and has welcomed the role. She will assume Chair of the Audit and Risk Committee and the Remuneration and Evaluation Committee.

Ms MacLeman is an experienced director and former executive having held senior leadership positions across pharmaceutical, biotechnology and medical technologies in corporate, medical, commercial and business development both domestically and overseas. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector and has been appointed to several academic and government advisory boards. Sue possesses a broad industry knowledge with a strategic and commercial mindset.

Rhythm Executive Chair, Otto Buttula, commented:

"In the short period of time Sue has been on the Rhythm Board, she has impressed both the executive and Board with her depth of knowledge, professional networks and strategic input into the various facets and challenges faced as the Company embarks upon its commercialisation path.

We believe that creating this new position on the Board not only enhances the Company's ability to leverage Sue's expertise, but importantly it elevates her independent director influence and puts in place a new governance regime outside of the executive.

We believe this will allow the executive to drive our strategic imperatives forward, facilitated by independent oversight. Overall, we are delighted that she has agreed to accept this appointment."

Independent Deputy Chair, Ms Sue MacLeman, commented:

"I am delighted to be appointed Independent, Deputy Chair of Rhythm. With the support of the Board and Executive I am absolutely committed to helping the Company build and commercialise on the progress achieved over recent years and deliver rewarding outcomes for all our stakeholders.

"Rhythm has important potential health outcomes available in its arsenal and successful market entry will play a meaningful and crucial role in the lives of patients not just in Australia, but internationally.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact: investor@rhythbio.com or on +61 3 8256 2880:

Mr Otto Buttula Executive Chairman T: +61 3 8256 2880	Ms Elena Deak Chief Commercial Officer T: +61 3 8256 2880	Mr Paul Smith CFO & Company Secretary T: +61 3 8256 2880
--	--	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.